Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission
- Monday, February 24, 2020, 7:01
- Finance
- Add a comment
SALT LAKE CITY, Feb. 24, 2020 /PRNewswire/ — Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of its Post Action meeting with the U.S. Food and Drug Administration (“FDA’) regarding its New Drug…
About the Author
adminasapcorp has written 39407 stories on this site.